Skip Navigation


Cardiovascular Research Advance Access first published online on March 19, 2009
This version [Corrected Proof] published online on April 8, 2009

Cardiovascular Research, doi:10.1093/cvr/cvp098
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
83/1/148    most recent
cvp098v2
cvp098v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rutkai, I.
Right arrow Articles by Bagi, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rutkai, I.
Right arrow Articles by Bagi, Z.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes

Ibolya Rutkai1, Attila Feher1, Nora Erdei1, Daniel Henrion2, Zoltan Papp1, Istvan Edes1, Akos Koller3,4, Gabor Kaley3 and Zsolt Bagi1,3,*

1 Division of Clinical Physiology, Institute of Cardiology, University of Debrecen, Debrecen, Hungary
2 University of Angers, CNRS UMR 6214, INSERM U771, Angers 49045, France
3 Department of Physiology, New York Medical College, Valhalla, NY 10595, USA
4 Department of Pathophysiology and Gerontology, University of Pecs, Pecs, Hungary

* Corresponding author. Tel: +1 914 594 4085; Fax: +1 914 594 4018. E-mail address: zsolt_bagi{at}nymc.edu

Aims: Type 2 diabetes mellitus is frequently associated with hypertension, but the underlying mechanisms are not completely understood. We tested the hypothesis that activation of type 1 prostaglandin E2 (PGE2) receptor (EP1) increases skeletal muscle arteriolar tone and blood pressure in mice with type 2 diabetes.

Methods and results: In 12-week-old, male db/db mice (with homozygote mutation in leptin receptor), systolic blood pressure was significantly elevated, compared with control heterozygotes. Isolated, pressurized gracilis muscle arterioles (~90 µm) of db/db mice exhibited an enhanced pressure- and angiotensin II (0.1–10 nM)-induced tone, which was reduced by the selective EP1 receptor antagonist, AH6809 (10 µM), to the level observed in arterioles of control mice. Exogenous application of PGE2 (10 pM–100 nM) or the selective agonist of the EP1 receptor, 17-phenyl-trinor-PGE2 (10 pM–100 nM), elicited arteriolar constrictions that were significantly enhanced in db/db mice (max: 31 ± 4 and 29 ± 5%), compared with controls (max: 20 ± 2 and 14 ± 3%, respectively). In the aorta of db/db mice, an increased protein expression of EP1, but not EP4, receptor was also detected by western immunoblotting. Moreover, we found that oral administration of the EP1 receptor antagonist, AH6809 (10 mg/kg/day, for 4 days), significantly reduced the systolic blood pressure in db/db, but not in control mice.

Conclusion: Activation of EP1 receptors increases arteriolar tone, which could contribute to the development of hypertension in the db/db mice.

KEYWORDS Diabetes; Hypertension; Arteriole; Prostanoid; EP receptor


Time for primary review: 31 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.